Searched for: in-biosketch:true
person:oneilk03
Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Virupakshaiah, Akash; Schoeps, Vinicius Andreoli; Race, Jonathan; Gambrah-Lyles, Claudia; Chang, Gina; Waltz, Michael; Nasr, Parinaz; Moseley, Carson E; Zamvil, Scott S; Edwards, Alice Rutatangwa; Francisco, Carla; Casper, T Charles; Rose, John W; Flanagan, Eoin P; Rodriguez, Moses; Tillema, Jan-Mendelt; Chitnis, Tanuja; Gorman, Mark P; Benson, Leslie A; Graves, Jennifer S; Rensel, Mary; Abrams, Aaron W; Krupp, Lauren B; O'Neill, Kimberly A; Lotze, Timothy E; Fisher, Kristen S; Shukla, Nikita Malani; Aaen, Gregory S; Wheeler, Yolanda S; Schreiner, Teri L; Waldman, Amy Tara; Chong, Janet; Waubant, Emmanuelle; Mar, Soe S
BACKGROUND AND OBJECTIVES/OBJECTIVE:The most effective treatment strategy to prevent relapses after a first myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) event remains unclear. Our objective was to evaluate the comparative effectiveness of maintenance therapies in preventing relapses in pediatric-onset MOGAD. METHODS:We analyzed prospectively collected data from November 2011 to August 2023 across 13 US pediatric neuroimmunology centers. Eligible patients had demyelinating disease onset before age 18 years, confirmed MOG-IgG positivity through cell-based assay, and negative aquaporin-4 IgG. Maintenance therapies were defined as ≥90 consecutive days of treatment and included IV immunoglobulin (IVIG), anti-CD20 therapy, oral corticosteroids, and other immunosuppressants. Two complementary approaches were used: (1) a primary full-course analysis using time-varying Cox proportional hazards models, adjusted for a priori-selected confounders, accounting for treatment changes throughout the disease course, and (2) a secondary early-course analysis using 1:1 propensity score-matched Cox models for the first qualifying treatment initiated within 90 days of onset, applying an intention-to-treat framework to minimize immortal time bias. RESULTS:< 0.001), and prior relapse count was a strong predictor of future relapse risk. DISCUSSION/CONCLUSIONS:In this large, prospective, multicenter pediatric MOGAD cohort, IVIG was the only treatment consistently associated with reduced relapse risk across both analytical approaches, supporting its potential role as first-line maintenance therapy. Anti-CD20 therapy showed directional trends warranting further investigation. Key limitations include potential residual confounding by indication and small sample sizes in certain treatment categories. Randomized controlled trials are needed to confirm these findings.
PMID: 42842889
ISSN: 1526-632x
CID: 6073977
Exploring Healthcare Continuity in Pediatric-Onset Multiple Sclerosis in the United States
Abrams, Aaron W; Waltz, Michael; Race, Jonathan; Casper, T Charles; Gambrah-Lyles, Claudia; O'Neill, Kimberly; Virupakshaiah, Akash; Fisher, Kristen S; Wright, Melissa A; Poisson, Kelsey E; Bernfeld, Eva-Chava M; Aaen, Gregory; Benson, Leslie A; Chitnis, Tanuja; Francisco, Carla; Gombolay, Grace Y; Gorman, Mark P; Graves, Jennifer S; Krupp, Lauren; Lotze, Timothy E; Mar, Soe; Ness, Jayne; Rensel, Mary; Rodriguez, Moses; Schreiner, Teri; Shukla, Nikita; Tillema, Jan-Mendelt; Weinstock-Guttman, Bianca; Wheeler, Yolanda; Waubant, Emmanuelle; Rose, John; ,
OBJECTIVE/UNASSIGNED:Little is known about shifting from pediatric to adult-focused multiple sclerosis (MS) care. This study aims to explore transition of care and follow-up in the US pediatric-onset MS (POMS) population. METHODS/UNASSIGNED:Surveys were distributed to 10 sites in the US Network of Pediatric MS Centers (US NPMSC) about transition-of-care practices. A cohort of POMS/clinically isolated syndrome (CIS) at 12 US NPMSC sites was analyzed. The primary comparison was between < 18 and ≥ 18-years of age. The primary outcome was 1- and 2-year lapse in last follow-up visit, measured from last recorded database visit to data lock date or, if ≥ 18 years of age, up to 1 year after a patient reached their site's typical transition age, if earlier. Secondary outcomes were baseline factors associated with follow-up lapse. The model was adjusted for preidentified confounders. RESULTS/UNASSIGNED: = 0.007). Platform injectable disease-modifying therapy was associated with greater and intravenous with lesser hazard of lapse in follow-up, while MS was associated with lower hazard than CIS. CONCLUSION/UNASSIGNED:Variable transition-of-care practices and barriers were reported by major US POMS centers. Before typical transition age, age ≥ 18 was associated with greater hazard of 1- and 2-year follow-up lapse than < 18. Developing standardized, targeted transition-of-care practices in POMS may be important.
PMCID:13580349
PMID: 42751265
ISSN: 2831-3267
CID: 6072931
Longitudinal stability of dietary intake patterns in pediatric-onset multiple sclerosis: A multicenter prospective cohort study
Virupakshaiah, Akash; Schoeps, Vinicius A; Chang, Gina; Waltz, Michael; Race, Jonathan; Mar, Soe; Francisco, Carla; Casper, T Charles; Rose, John; Rodriguez, Moses; Tillema, Jan-Mendelt; Chitnis, Tanuja; Gorman, Mark P; Benson, Leslie A; Graves, Jennifer S; Rensel, Mary; Abrams, Aaron; Krupp, Lauren B; O'Neill, Kimberly A; Lotze, Timothy E; Aaen, Gregory; Wheeler, Yolanda; Schreiner, Teri; Waldman, Amy T; Chong, Janet; Titcomb, Tyler J; Tremlett, Helen; Waubant, Emmanuelle
BACKGROUND:Diet may influence MS activity, but most studies use a single dietary measure. The stability of diet over time in pediatric-onset MS (POMS) is unclear. OBJECTIVES/OBJECTIVE:To evaluate the reproducibility and short-term temporal stability of dietary intake in youth with POMS using repeated food frequency questionnaires (FFQ). METHODS:This longitudinal study included participants with a baseline FFQ (the Block Kids Food Screener, 2014). Intraclass correlation coefficients (ICCs) were estimated using random-intercept mixed-effects models to quantify the relative contributions of between-person and within-person variability. Temporal trends in intake were assessed by modeling time since baseline as a fixed effect, using log-transformed dietary variables to estimate percent change over time. RESULTS:Of 419 FFQs from 195 participants, 140 (71.8%) completed ≥2 FFQs over a median of 6.5 months (range 2.8-18). ICCs ranged from 0.41 to 0.78 across dietary measures, with the highest reproducibility observed for vegetables and fiber (ICCs 0.78 and 0.72). Log-transformed models showed small declines in several nutrients over time, corresponding to <10% change over a six-month period. CONCLUSIONS:Dietary intake demonstrated moderate to good reproducibility over the 6 to 18 month follow-up period. Vegetable and fiber intake had the strongest reliability. These findings suggest that reported dietary intake assessed by a single or infrequent FFQ may remain reasonably stable over a 6- to 18-month period in longitudinal POMS studies. However, the moderate-to-good reproducibility observed indicates that within-person variability persists and may attenuate diet-disease associations when only a single dietary assessment is available.
PMID: 42697107
ISSN: 2211-0356
CID: 6072028
Adaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach
Gambrah-Lyles, Claudia; Abrams, Aaron W; Loud, Sara; Schmidt, Hollie; Blosberg, Emily; Wright, Melissa; Poisson, Kelsey E; Fisher, Kristen S; O'Neill, Kimberly A; Virupakshaiah, Akash; Rose, John W
BACKGROUND/UNASSIGNED:Pediatric-onset multiple sclerosis (POMS) is a chronic, progressive neurologic condition requiring lifelong management and coordinated transition from pediatric to adult care. Evidence-based guidelines identify transition readiness assessment as a core component of successful transition; however, most POMS clinics do not formally assess readiness, and existing tools do not address POMS-specific challenges, such as fluctuating disability, complex treatment regimens, and cognitive impairment. This gap underscores the need for a transition readiness measure tailored to POMS. OBJECTIVE/UNASSIGNED:This paper aims to describe a stakeholder-engaged, implementation science-guided protocol for adapting the Transition Readiness Assessment Questionnaire (TRAQ) version 6.0 to reflect the unique developmental and clinical needs of youth with POMS. METHODS/UNASSIGNED:Using adaptation and participatory research as our guiding implementation strategies, surveys will be administered to patients, caregivers, and clinicians to identify barriers to and facilitators of transition to adult care and define essential self-management competencies in POMS. Survey content will be informed by constructs from the dynamic adaptation process framework and existing TRAQ 6.0 domains. Identified competencies will be refined using a Delphi consensus process. Through cognitive interviewing and a multidisciplinary focus group of collaborators, the adapted measure will be reviewed to assess clarity, relevance, and perceived clinical utility. RESULTS/UNASSIGNED:This project will generate a consensus-driven set of POMS-specific transition competencies and systematically adapt the TRAQ 6.0 to the POMS population. This study was funded in July 2025. The health care provider survey was disseminated in November 2025 across the 27 sites in the US Network of Pediatric Multiple Sclerosis Centers. The patient and caregiver surveys have been finalized, and distribution is projected to begin in June 2026, with a target of 15 patients and 15 caregivers. As of manuscript submission, no patients or caregivers have been recruited, and data analysis has not yet started. Data collection is expected to conclude by the end of 2026, and results are anticipated for publication in 2027. CONCLUSIONS/UNASSIGNED:This protocol outlines a rigorous, replicable approach to adapting a validated transition readiness measure to POMS. The adapted TRAQ 6.0 will support evidence-based transition planning and inform future psychometric testing and implementation research to improve the care of patients with POMS as they age.
PMCID:13293475
PMID: 42341234
ISSN: 1929-0748
CID: 6055912
Childhood adversity, allostatic load and epigenetic signatures in paediatric and adult-onset multiple sclerosis
O'Neill, Kimberly A; van der Veer, Bernard K; Charvet, Leigh; Azmy, Nadine; Friedman, Steven; Hu, Jiyuan; Lei, Kevin; Ortiz, Robin; Pehel, Shayna; Shi, Yidan; Sosa, Anna; Koh, Kian Peng; Maletic-Savatic, Mirjana; Krupp, Lauren B
Childhood adversity is increasingly recognized as a critical modifier of neurologic disorder development and disease severity, including in the neuroimmune disorder multiple sclerosis (MS). While previous studies have linked early-life adversity to increased MS susceptibility and more severe disease, the underlying biological mechanisms remain poorly understood. This study investigated associations between childhood adversity and MS clinical features, with a focus on two potential pathogenic mechanisms: allostatic load and epigenetic modifications. We evaluated 60 consecutively enrolled young adults with MS; 30 with paediatric-onset MS (POMS) and 30 with adult-onset MS (AOMS). At time of enrolment in this cross-sectional study, participants had MS disease duration of 6 years on average. POMS participants were mean 22.09 (2.66) years and AOMS participants were mean 32.41 (2.19) years old. 62% of participants were female. Childhood adversity was defined using a composite index of individual, family and socioeconomic measures captured by the adverse childhood experiences questionnaire, parental education level and estimated household income during childhood. Clinical outcomes included patient-reported SymptoMScreen questionnaire regarding MS symptom burden and MS neurologist-assessed disability using the Expanded Disability Status Scale (EDSS) of the participant's neurologic exam at the time of enrolment. Circulating biomarkers of allostatic load and genome-wide epigenetic profiles (DNA methylation via RRBS; reduced representation bisulfite sequencing) were also assessed. A history of high childhood adversity was associated with significantly greater patient-reported MS symptom burden (P = 0.001) and higher neurologist-reported EDSS disability scores (P = 0.028), independent of disease duration or timing of treatment initiation. There were no differences between childhood adversity and circulating biomarkers of allostatic load. While childhood adversity was not associated with global epigenetic changes across the entire cohort, stratified analysis revealed divergent methylation patterns by age of MS onset: POMS participants with childhood adversity had increased DNA methylation, whereas AOMS participants with childhood adversity showed decreased methylation compared to individuals without childhood adversity. None of the observed clinical and biologic differences were explained by differences in disease duration or the interval between symptom onset and treatment initiation. Our findings suggest that childhood adversity is associated with increased MS symptom burden and neurologic disability in young adults with MS. Childhood adversity may differentially shape the epigenome, depending on the age of MS onset, with potential implications for disease trajectory and therapeutic vulnerability. These results support the biological embedding of childhood adversity in MS and highlight the need for age- and exposure-sensitive approaches to understanding MS pathogenesis across the lifespan.
PMCID:12917236
PMID: 41728265
ISSN: 2632-1297
CID: 6009652
Finding community for early career health equity researchers
Suarez, Javier A; O'Neill, Kimberly A; Berkman, Jillian
Health equity research in neurology and neuroscience faces a unique challenge in the current United States climate of funding scarcity and prioritization of other research topics. The low funding contrasts with rising interest and scholarship in the field. Neuroscientists in the early phases of their career are particularly vulnerable to the detrimental effects of reduced funding due to their relatively lower publication history and established sources of support for projects. Here, we introduce the Early Career Network within the Society of Equity Neuroscience (SEQUINS). The group is dedicated to the support of early-career neurologists and neuroscientists who pursue health equity neuroscience research. We will accomplish this via a combination of virtual and in-person events as well as the establishment of a robust community of scientists. Together, we will foster camaraderie, solidarity, and shared interests to propel the field of health equity neuroscience forward.
PMCID:12857917
PMID: 41626036
ISSN: 3050-8401
CID: 5999502
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis
Abrams, Aaron W; Waltz, Michael; Casper, T Charles; Aaen, Gregory; Benson, Leslie A; Bernfeld, Eva-Chava M; Charvet, Leigh E; Chitnis, Tanuja; Francisco, Carla; Gorman, Mark P; Graves, Jennifer S; Krupp, Lauren; O'Neill, Kimberly; Lotze, Timothy E; Mar, Soe; Ness, Jayne; Rensel, Mary; Rodriguez, Moses; Rose, John; Rutatangwa, Alice; Schreiner, Teri; Shukla, Nikita; Tillema, Jan-Mendelt; Weinstock-Guttman, Bianca; Wheeler, Yolanda; Waubant, Emmanuelle; Krysko, Kristen M; ,
OBJECTIVE:To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. METHODS:Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. RESULTS:A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88). INTERPRETATION/CONCLUSIONS:Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.
PMID: 41195640
ISSN: 1531-8249
CID: 5960042
Incorporating Measures of Cognitive Processing Speed and Brain Volume in Clinical Management of Pediatric Onset Multiple Sclerosis
Sosa, Anna; O'Neill, Kimberly A; Billiet, Thibo; Chen, Jingyun; Couvreur, Laura; Denissen, Stijn; Lustberg, Matthew; Pehel, Shayna; Ribbens, Annemie; Krupp, Lauren
BACKGROUND:While cognitive processing and brain volume assessments are commonly used in multiple sclerosis (MS) research, they are not routinely incorporated into clinical care. Advances in neuroimaging software now allow for brain volume measurement to be incorporated into standard practice and guide clinical decision-making. METHODS:In this single-center, outpatient, cohort study, pediatric-onset multiple sclerosis (POMS) patients underwent at least two volumetric brain magnetic resonance imagings (MRIs) and two Symbol Digit Modalities Tests (SDMT) at least 6 months apart. Associations were analyzed using Pearson's correlation coefficient and linear regressions. RESULTS:Forty patients with POMS were included. The first volumetric brain MRI occurred at a median of 2.7 years after symptom onset. At the first volumetric MRI, 12% of patients had white matter brain volumes within 1% of normative values (n = 2000 healthy controls). Whole brain volume percentile (r = 0.4, P = 0.01), white matter percentile (r = 0.4, P = 0.01), and white matter lesion volume (r = -0.4, P = 0.005) were associated with SDMT score. Annualized percent brain volume change of the hippocampus (measured a median of 1.6 years apart) significantly correlated with follow-up SDMT (r = 0.4, P = 0.02), and annualized percent brain volume change of the thalamus correlated with annual change in SDMT z-score (r = 0.4, P = 0.009). CONCLUSIONS:Application of new software allows for volumetric assessment to be incorporated into clinical scans and provides clinicians with added data for patient management. This is critical for patients with POMS as the neurological examination often shows few to no abnormalities. Furthermore, a subset of POMS patients have smaller than expected brain volume which links to subsequent poorer cognitive performance.
PMID: 41270335
ISSN: 1873-5150
CID: 5976142
MULTIPLE SCLEROSIS JOURNAL
Soni, Ria H.; Garcia, Mekka; Oak, Eunhye; Applbaum, Eliana J.; Rajagopalan, Logi; Krupp, Lauren B.; O\Neill, Kimberly A.
ISI:001402775600001
ISSN: 1352-4585
CID: 5957752
Why Supporting Children Is Key for Lifelong Brain Health [Editorial]
O'Neill, Kimberly A
PMID: 41065378
ISSN: 1708-8283
CID: 5952152